Send to

Choose Destination
Hepatology. 2017 Apr;65(4):1369-1383. doi: 10.1002/hep.28973. Epub 2017 Feb 7.

Hepatocyte autotaxin expression promotes liver fibrosis and cancer.

Author information

Division of Immunology, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece.
Department of Histology and Embryology, School of Medicine, University of Athens, Athens, Greece.
Laboratory of Biochemistry, Technological Educational Institute of Thessaly, Larissa, Greece.
Biomedical Research Foundation, Academy of Athens, Athens, Greece.
Institute for Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece.


Autotaxin (ATX) is a secreted lysophospholipase D that catalyzes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor-like lysophospholipid. Increased ATX expression has been detected in various chronic inflammatory disorders and different types of cancer; however, little is known about its role and mode of action in liver fibrosis and cancer. Here, increased ATX expression was detected in chronic liver disease (CLD) patients of different etiologies, associated with shorter overall survival. In mice, different hepatotoxic stimuli linked with the development of different forms of CLDs were shown to stimulate hepatocyte ATX expression, leading to increased LPA levels, activation of hepatic stellate cells (HSCs), and amplification of profibrotic signals. Hepatocyte-specific, conditional genetic deletion and/or transgenic overexpression of ATX established a liver profibrotic role for ATX/LPA, whereas pharmacological ATX inhibition studies suggested ATX as a possible therapeutic target in CLDs. In addition, hepatocyte ATX ablation and the consequent deregulation of lipid homeostasis was also shown to attenuate hepatocellular carcinoma (HCC) development, thus implicating ATX/LPA in the causative link of cirrhosis and HCC.


ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target. (Hepatology 2017;65:1369-1383).

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center